drugset
drugset / Trial / NCT04976140

Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

NCT04976140 ↗

Phase 1/2 Completed 9 enrolled Paean Biotechnology Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

To determine the maximum tolerated dose (MTD) based on the safety and tolerability after single-dose administration of PN-101 in patients with refractory polymyositis or dermatomyositis. To explore the efficacy after single-dose administration of PN-101 in patients with refractory polymyositis or dermatomyositis.

Timeline

Start
2021-12-15
Primary completion
2023-10-06
Completion
2023-10-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject PN-101 Unknown — Intravenous

Indications

dermatomyositis